Previous 10 | Next 10 |
GERMANTOWN, Md. , April 29, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its majority owned Intrexon Health subsidiary Xogenex, today announced that...
GERMANTOWN, Md. , April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, ...
Fibrocell Science ( FCSC ) was able to establish a partnership with privately held Castle Creek Pharmaceuticals . This partnership will help Fibrocell to advance its gene therapy product FCX-007 to treat patients with a rare life-threatening disease known as recessive dystrophic epidermolys...
MAYNARD, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (Nasdaq: X...
Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem. More news on: SPDR Biotech ETF, SPDR S&...
OXFORD, England , April 16, 2019 /PRNewswire/ -- Oxitec Ltd., a UK-based biotechnology company that pioneered the use of biologically-engineered insects to control disease-spreading mosquitoes and crop-destroying agricultural pests and a wholly-owned subsidiary of Intrexon (NASDAQ: X...
- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease Priority Review Voucher - - Phase 3 clinical trial (DEFI-RDEB) in...
GERMANTOWN, Md. , April 10, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Thomas D. Reed , PhD, Founder and Chief Science Officer...
MAYNARD, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (Nasdaq: X...
Oxitec Ltd., a wholly-owned subsidiary of Intrexon (NASDAQ: XON ), has entered into a second agreement with a collaborator to advance the next phase of development of its self-limiting fall armyworm control solution. More news on: Intrexon Corporation, Healthcare stocks news, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares PR Newswire GERMANTOWN, Md. , Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously ann...
Pioneer Natural Resources (PXD) is well positioned to benefit from the recovery of the global economy because the demand for oil and natural gas will rise with the resumption of industrial operations. Also, the company’s progress on strategic acquisitions and in providing unique scale ...
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference - Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference - PR Newswire GERMANTOWN, Md. , Jan. 6, 2021 /PRNewswire/ -- Precigen, In...